目的 探討培美曲塞聯(lián)合卡鉑與順鉑對復發(fā)性卵巢上皮癌患者的療效及安全性。方法 回顧性選擇濮陽市油田總醫(yī)院2012年1月-2015年12月收治的53例復發(fā)性卵巢上皮癌患者，根據(jù)化療方法的不同分為A組及B組，A組26例，采用培美曲塞聯(lián)合順鉑治療，B組27例，采用培美曲塞聯(lián)合卡鉑治療，對比兩組的臨床療效、無進展生存期及不良反應。結果 A組治療有效率為34.6%，B組為40.7%，兩組有效率對比無統(tǒng)計學意義。A組平均無進展生存期為（9.1±1.9）個月，B組為（9.7±1.8）個月，組間對比無統(tǒng)計學意義。A、B兩組的Ⅲ~Ⅳ血液學毒性、乏力、Ⅲ~Ⅳ消化道反應對比無統(tǒng)計學意義；而B組的Ⅲ~Ⅳ周圍神經(jīng)病變、Ⅲ~Ⅳ脫發(fā)、發(fā)熱發(fā)生率明顯低于A組，差異有統(tǒng)計學意義（P<0.05）。結論 培美曲塞聯(lián)合卡鉑與培美曲塞聯(lián)合順鉑對復發(fā)性卵巢上皮癌的效果相當，但培美曲塞聯(lián)合卡鉑的安全性較高。

Objective To investigate the efficacy and safety of pemetrexed combined with carboplatin and cisplatin in patients with recurrent ovarian epithelial cancer.Methods 53 cases with recurrent ovarian epithelial cancer from Jan.2012 to Dec.2015 in our hospital were retrospective selection,who were divided into the group A (26 cases) and group B (27 cases),group A were given pemetrexed combination with cisplatin,group B were given pemetrexed combination with carboplatin,the clinical efficacy,progression-free survival and adverse events of two groups were compared.Results The clinical efficacy of group A was 34.6%,the group B was 40.7%,which in two groups had no significant difference.The progression-free survival of group A was (9.1 ±1.9) months,which in the group B was (9.7 ±1.8) months.The Ⅲ-Ⅳ hematological toxicity,weak,Ⅲ-Ⅳ digestive tract reaction of two groups had no significant difference.The Ⅲ-Ⅳ peripheral neuropathy,Ⅲ-Ⅳ hair loss,fever of group B were lower than group A (P< 0.05).Conclusion Pemetrexed combined with carboplatin and pemetrexed combined with cisplatin was equally effective in recurrent ovarian epithelial cancer,while pemetrexed combined with carboplatin was safer.